{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adenosine+arm&page=3", "query": { "intervention": "Adenosine arm", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 105, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adenosine+arm&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adenosine+arm&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T14:50:13.359Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03236311", "title": "A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microvascular Coronary Artery Disease" ], "interventions": [ { "name": "SAR407899", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Adenosine", "type": "DRUG" }, { "name": "Regadenoson", "type": "DRUG" }, { "name": "13N-ammonia", "type": "DRUG" }, { "name": "82Rubidium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-10-12", "completion_date": "2018-07-23", "has_results": true, "last_update_posted_date": "2022-03-24", "last_synced_at": "2026-11-15T14:50:13.359Z", "location_count": 6, "location_summary": "Los Angeles, California • Jacksonville, Florida • Wellington, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Wellington", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03236311" }, { "nct_id": "NCT06228456", "title": "Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Ticagrelor 60mg", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-04-01", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-11-15T14:50:13.359Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06228456" }, { "nct_id": "NCT06561360", "title": "A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hairy Cell Leukemia" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Cladribine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2024-09-09", "completion_date": "2027-09-09", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-11-15T14:50:13.359Z", "location_count": 10, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Basking Ridge, New Jersey + 7 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06561360" }, { "nct_id": "NCT00509769", "title": "A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Trastuzumab emtansine [Kadcyla]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 112, "start_date": "2007-07", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2013-04-02", "last_synced_at": "2026-11-15T14:50:13.359Z", "location_count": 40, "location_summary": "Little Rock, Arkansas • Denver, Colorado • Washington D.C., District of Columbia + 34 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Davie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509769" }, { "nct_id": "NCT05047172", "title": "Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intracranial Arteriosclerosis", "Stroke" ], "interventions": [ { "name": "Ticagrelor + Aspirin", "type": "DRUG" }, { "name": "Rivaroxaban + Aspirin", "type": "DRUG" }, { "name": "Clopidogrel + Aspirin", "type": "DRUG" }, { "name": "Risk Factor Management", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 1683, "start_date": "2022-08-02", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-15T14:50:13.359Z", "location_count": 114, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05047172" }, { "nct_id": "NCT04296942", "title": "BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer", "HER2+ Breast Cancer", "Hormone Receptor Negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Brachyury-TRICOM", "type": "BIOLOGICAL" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "M7824", "type": "BIOLOGICAL" }, { "name": "Ado-trastuzumab emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-05-04", "completion_date": "2021-10-22", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-11-15T14:50:13.359Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04296942" }, { "nct_id": "NCT03955471", "title": "Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 41, "start_date": "2019-10-03", "completion_date": "2022-01-12", "has_results": true, "last_update_posted_date": "2022-09-10", "last_synced_at": "2026-11-15T14:50:13.359Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Duarte, California • Newport Beach, California + 22 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Solvang", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03955471" }, { "nct_id": "NCT00722124", "title": "S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Tobacco Dependence" ], "interventions": [ { "name": "S-Adenosyl-L-Methionine", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2008-09", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2011-09-09", "last_synced_at": "2026-11-15T14:50:13.359Z", "location_count": 2, "location_summary": "Rochester, Minnesota • La Crosse, Wisconsin", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "La Crosse", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722124" }, { "nct_id": "NCT03690544", "title": "Apremilast for RAS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Recurrent Aphthous Stomatitis" ], "interventions": [ { "name": "Apremilast 30mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2018-10-12", "completion_date": "2021-07-14", "has_results": true, "last_update_posted_date": "2022-07-14", "last_synced_at": "2026-11-15T14:50:13.359Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03690544" }, { "nct_id": "NCT03535298", "title": "Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Early Highly Effective Therapies Group", "type": "DRUG" }, { "name": "Escalation Therapies Group", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 800, "start_date": "2019-01-03", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-11-15T14:50:13.359Z", "location_count": 15, "location_summary": "Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03535298" } ] }